Ranbaxy Recalls Drug in the U.S.

Ranbaxy Laboratories is voluntarily recalling a batch of its best-selling anti-acne drug remaining in the US market that was banned earlier by the American regulator, after it failed a dissolution test to assess the efficacy, uniformity and stability of the dosage.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.